



# Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024

June 2024: Complimentary Abstract / Table of Contents

**PEAK**  
MATRIX®

Life Sciences Business Process

 Everest Group®

# Our research offerings

This report is included in the following research program(s):

## Life Sciences Business Process

- ▶ Amazon Web Services (AWS)
- ▶ Application Services
- ▶ Artificial Intelligence (AI)
- ▶ Asset and Wealth Management
- ▶ Banking and Financial Services Business Process
- ▶ Banking and Financial Services Information Technology
- ▶ Catalyst™
- ▶ Clinical Development Technology
- ▶ Cloud and Infrastructure
- ▶ Contingent Staffing
- ▶ Contingent Workforce Management
- ▶ Customer Experience Management Services
- ▶ CX Excellence
- ▶ CXM Technology
- ▶ Cybersecurity
- ▶ Cyber Threat Detection and Response
- ▶ Data and Analytics
- ▶ Digital Adoption Platforms
- ▶ Digital Services
- ▶ Digital Workplace
- ▶ Employee Experience Management (EXM) Platforms
- ▶ Employer of Record (EOR)
- ▶ Engineering Research and Development
- ▶ Enterprise Platform Services
- ▶ Exponential Technologies
- ▶ Finance and Accounting
- ▶ Financial Crime and Compliance Operations
- ▶ Financial Services Technology (FinTech)
- ▶ Forces & Foresight
- ▶ GBS Talent Excellence
- ▶ Global Business Services
- ▶ Google Cloud
- ▶ HealthTech
- ▶ Human Resources
- ▶ Insurance Business Process
- ▶ Insurance Information Technology
- ▶ Insurance Technology (InsurTech)
- ▶ Insurance Third-Party Administration (TPA) Services
- ▶ Intelligent Document Processing
- ▶ Interactive Experience (IX) Services
- ▶ IT Services Excellence
- ▶ IT Talent Excellence
- ▶ Life Sciences Business Process
- ▶ Life Sciences Commercial Technologies
- ▶ Life Sciences Information Technology
- ▶ Locations Insider™
- ▶ Marketing Services
- ▶ Market Vista™
- ▶ Microsoft Azure
- ▶ Microsoft Business Application Services
- ▶ Modern Application Development (MAD)
- ▶ Mortgage Operations
- ▶ Multi-country Payroll
- ▶ Network Services and 5G
- ▶ Oracle Services
- ▶ Outsourcing Excellence
- ▶ Payer and Provider Business Process
- ▶ Payer and Provider Information Technology
- ▶ Price Genius – AMS Solution and Pricing Tool
- ▶ Pricing Analytics as a Service
- ▶ Process Intelligence
- ▶ Process Orchestration
- ▶ Procurement and Supply Chain
- ▶ Recruitment
- ▶ Retail and CPG IT Services
- ▶ Retirement Technologies
- ▶ Revenue Cycle Management
- ▶ Rewards and Recognition
- ▶ SAP Services
- ▶ Service Optimization Technologies
- ▶ Software Product Engineering Services
- ▶ Supply Chain Management (SCM) Services
- ▶ Sustainability Technology and Services
- ▶ Talent Genius™
- ▶ Technology Skills and Talent
- ▶ Trust and Safety
- ▶ Value and Quality Assurance (VQA)

If you want to learn whether your organization has a membership agreement or request information on pricing and membership options, please contact us at [info@everestgrp.com](mailto:info@everestgrp.com)

Learn more about  
our custom research capabilities

Benchmarking

Contract assessment

Peer analysis

Market intelligence

Tracking: providers, locations, risk,  
technologies

Locations: costs, skills, sustainability,  
portfolios

# Contents

4	<b>Introduction and overview</b>	26	<b>Major Contenders</b>
5	Research methodology	27	DXC Technology
6	Key information on the report	28	HCLTech
7	Introduction	29	ICON plc
8	Regulatory and medical affairs value chain	30	Indegene
9	Summary of key messages	31	Medpace
10	<b>Regulatory and Medical Affairs Operations</b>	32	Navitas Life Sciences
	<b>PEAK Matrix® characteristics</b>	33	PPD
11	PEAK Matrix framework	34	ProPharma Group
13	Everest Group PEAK Matrix for Regulatory and Medical Affairs operations	35	Syneos Health
14	Characteristics of Leaders, Major Contenders, and Aspirants	36	Tech Mahindra
15	Provider capability summary dashboard	37	Wipro
19	<b>Enterprise sourcing considerations</b>	38	<b>Aspirants</b>
19	<b>Leaders</b>	39	CliniRx
20	Accenture	40	ProTrials
21	Cencora Pharmalex	41	Quanticate
22	Freyr	42	<b>Appendix</b>
23	Genpact	43	Glossary
24	IQVIA	44	Research calendar
25	Parexel		

For more information on this and other research published by Everest Group, please contact us:

**Abhishek AK**, Vice President

**Lloyd Fernandes**, Practice Director

**Arundhati Goel**, Senior Analyst

**Gokul Janardhan**, Senior Analyst

**Ishita Aggarwal**, Analyst

Copyright © 2024 Everest Global, Inc.

We encourage you to share these materials internally in accordance with your license. Sharing these materials outside your organization in any form – electronic, written, or verbal – is prohibited unless you obtain the express, prior, and written consent of Everest Global, Inc. It is your organization's responsibility to maintain the confidentiality of these materials in accordance with your license of them.

# Introduction

The landscape of regulatory requirements is undergoing drastic changes, presenting enterprises with an array of challenges. Challenges such as navigating complex compliance frameworks, staying abreast of emerging regulations, and managing diverse geographical requirements have become formidable obstacles for enterprises striving for regulatory compliance and market access. Consequently, an increasing number of enterprises are turning to external service providers equipped with specialized knowledge and technological expertise to navigate these intricate regulatory landscapes efficiently.

To meet the escalating demand for regulatory and medical affairs support, service providers are proactively fortifying their capabilities and offerings. Recognizing the critical need for adaptable solutions, providers are investing substantially in technological advancements expanding their portfolio to encompass cutting-edge tools and platforms tailored to streamline regulatory processes. Moreover, to offer enhanced value and accessibility, providers are augmenting their global footprint establishing

localized support networks to fulfill the nuanced requirements of diverse markets.

In this report, we present an assessment and detailed profiles of 20 service providers featured on the Regulatory and Medical Affairs Operations PEAK Matrix®. The assessment is based on Everest Group's annual RFI process for calendar year 2024, interactions with leading regulatory and medical affairs providers, client reference checks, and an ongoing analysis of the regulatory and medical affairs BPS market.

**This report includes the profiles of the following 20 leading service providers featured on the Regulatory and Medical Affairs Operations PEAK Matrix:**

- **Leaders:** Accenture, Cencora PharmaLex, Freyr, Genpact, ICON, IQVIA, and Parexel
- **Major Contenders:** DXC Technology, HCLTech, Indegene, Medpace, Navitas life Sciences, PPD, ProPharma Group, Syneos Health, Tech Mahindra, and Wipro
- **Aspirants:** CliniRx, ProTrials, and Quanticate

## Scope of this report

**Geography:** Global

**Industry:** Life sciences

**Services:** Life sciences regulatory and medical affairs operations

# Regulatory and Medical Affairs Operations – services PEAK Matrix® characteristics

## Leaders

Accenture, Cencora PharmaLex, Freyr, Genpact, ICON, IQVIA, and Parexel

- Leaders have a global delivery footprint, and they exhibit capabilities to serve clients from all tiers – ranging from emerging biotechs to large established pharma and MedTech enterprises
- Along with driving superior client engagement, they have showcased high levels of proactiveness in taking their innovations and next-generation service offerings to clients, thereby positioning themselves as strategic partners. Their offerings, coupled with consulting-based solutions, are appreciated by clients
- The majority of Leaders have broad coverage across the regulatory and medical affairs value chain and can offer one-stop solutions to enterprises

## Major Contenders

DXC Technology, HCLTech, Indegene, Medpace, Navitas life Sciences, PPD, ProPharma Group, Syneos Health, Tech Mahindra, and Wipro

- While Major Contenders may not have an integrated and comprehensive coverage of the regulatory and medical affairs operations value chain, they have been able to deliver value by strengthening their capabilities through investments
- Few Major Contenders have also made small acquisitions to expand their breadth and coverage
- To bridge the gap with Leaders, Major Contenders are investing in cutting-edge technologies and AI/ML solutions, while simultaneously increasing their scale of operations

## Aspirants

CliniRx, ProTrials, and Quanticate


- The majority of Aspirants are focused on selective areas, be it in terms of value chain segments, buyer type, or geographies
- Aspirants in the regulatory and medical affairs operations arena seek to carve out their niche by strategically directing investments toward unique capabilities and specialized use cases, positioning themselves for future growth and innovation in the market
- They have relatively limited domain and technology capabilities compared to the Leaders and Major Contenders

# This study offers three distinct chapters providing a deep dive into key aspects of life sciences regulatory and medical affairs operations market; below are three charts to illustrate the depth of the report

## Everest Group PEAK Matrix® Assessment 2024

### Everest Group Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024<sup>1,2</sup>

● Leaders ● Major Contenders ○ Aspirants



1 Assessment for CliniRx, Cencora PharmaLex, ICON, Medpace, Navitas Life Sciences, Parexel, PPD, ProTrials, Quanticate and Syneos Health excludes service provider inputs and is based on Everest Group's proprietary Transaction Intelligence (TI) database, service provider public disclosures, and Everest Group's interaction with buyers. For these companies, Everest Group's data for assessment may be less complete

2 The assessments for IQVIA and ProPharma were assisted by the respective service providers through briefing calls  
Source: Everest Group (2024)

## Capability assessment

Illustrative example

Measure of capability: ○ Low ● High

Providers	Market impact				Vision and capability				
	Market adoption	Portfolio mix	Value delivered	Overall	Vision and strategy	Scope of services offered	Innovation and investments	Delivery footprint	Overall
Provider 1	●	●	●	●	●	●	●	●	●
Provider 2	●	○	●	●	●	○	●	○	●
Provider 3	●	●	●	●	●	●	●	●	●
Provider 4	○	○	●	●	○	○	●	●	●
Provider 5	●	●	●	●	●	●	●	●	●
Provider 6	○	○	●	○	●	○	○	●	○

## Everest Group's remarks on providers

Illustrative example

Measure of capability: ○ Low ● High

Market impact				Vision and capability				
Market adoption	Portfolio mix	Value delivered	Overall	Vision and strategy	Scope of services offered	Innovation and investments	Delivery footprint	Overall
○	●	●	●	●	○	○	○	●

### Strengths

- With strong consulting capabilities to complement its life science operations, Provider 1 continues to invest significantly in building its partnership ecosystem
- Provider 1 continues to expand its technological offerings with its proprietary platforms ABC and XYZ, which have sustained traction from clients. They have further invested in multiple service providers such as XYZ to scale their digital capabilities

### Limitations

- Unlike its peers, Provider 1 is yet to establish a strong foothold in the medical devices segment with its client base largely skewed toward biopharma
- Referenced clients highlighted proactiveness and transparency in relationship management as areas of improvement

# Research calendar

## Life Sciences Business Process

	Published	Current release	Planned
Reports title	Release date		
Navigating Economic, Geopolitical, and Regulatory Uncertainty in the Life Sciences Industry			April 2023
Life Sciences Sales and Marketing Operations – Provider Compendium 2023			June 2023
Life Sciences Operations PEAK Matrix® Assessment 2023			September 2023
Adapting Commercial Models for Success in the Life Sciences Industry			October 2023
MedTech Operations PEAK Matrix® Assessment 2023			November 2023
Life Sciences Operations – Provider Compendium 2024			February 2024
MedTech Operations – Provider Compendium 2024			March 2024
Life Sciences Enterprise Sourcing Considerations			May 2024
<b>Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024</b>			<b>June 2024</b>
Patient Recruitment Services – Market Report 2024			Q2 2024
Generative AI in Life Sciences: Moving from Ideas to Operationalization			Q3 2024
Data and Analytics in Life Sciences Commercial PEAK Matrix® Assessment 2024			Q3 2024
Pharmacovigilance Operations PEAK Matrix® Assessment 2024			Q4 2024
Pharmacovigilance: State of the Market			Q4 2024
Pharmacovigilance Operations Provider Compendium 2024			Q4 2024

Note: [Click](#) to see a list of all of our published Life Sciences Business Process reports



# Stay connected

Dallas (Headquarters)

info@everestgrp.com

+1-214-451-3000

Bangalore

india@everestgrp.com

+91-80-61463500

Delhi

india@everestgrp.com

+91-124-496-1000

London

unitedkingdom@everestgrp.com

+44-207-129-1318

Toronto

canada@everestgrp.com

+1-214-451-3000

Website

everestgrp.com

Blog

everestgrp.com/blog

Follow us on



Everest Group is a leading research firm helping business leaders make confident decisions. We guide clients through today's market challenges and strengthen their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. Our deep expertise and tenacious research focused on technology, business processes, and engineering through the lenses of talent, sustainability, and sourcing delivers precise and action-oriented guidance. Find further details and in-depth content at [www.everestgrp.com](http://www.everestgrp.com).

## Notice and disclaimers

**Important information. Please review this notice carefully and in its entirety. Through your access, you agree to Everest Group's terms of use.**

Everest Group's Terms of Use, available at [www.everestgrp.com/terms-of-use/](http://www.everestgrp.com/terms-of-use/), is hereby incorporated by reference as if fully reproduced herein. Parts of these terms are pasted below for convenience; please refer to the link above for the full version of the Terms of Use.

Everest Group is not registered as an investment adviser or research analyst with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (FINRA), or any state or foreign securities regulatory authority. For the avoidance of doubt, Everest Group is not providing any advice concerning securities as defined by the law or any regulatory entity or an analysis of equity securities as defined by the law or any regulatory entity.

All Everest Group Products and/or Services are for informational purposes only and are provided "as is" without any warranty of any kind. You understand and expressly agree that you assume the entire risk as to your use and any reliance upon any Product or Service. Everest Group is not a legal, tax, financial, or investment advisor, and nothing provided by Everest Group is legal, tax, financial, or investment advice. Nothing Everest Group provides is an offer to sell or a solicitation of an offer to purchase any securities or instruments from any entity. Nothing from Everest Group may be used or relied upon in evaluating the merits of any investment. Do not base any investment decisions, in whole or part, on anything provided by Everest Group.

Products and/or Services represent research opinions or viewpoints, not representations or statements of fact. Accessing, using, or receiving a grant of access to an Everest Group Product and/or Service does not constitute any recommendation by Everest Group that recipient (1) take any action or refrain from taking any action or (2) enter into a particular transaction. Nothing from Everest Group will be relied upon or interpreted as a promise or representation as to past, present, or future performance of a business or a market. The information contained in any Everest Group Product and/or Service is as of the date prepared, and Everest Group has no duty or obligation to update or revise the information or documentation. Everest Group may have obtained information that appears in its Products and/or Services from the parties mentioned therein, public sources, or third-party sources, including information related to financials, estimates, and/or forecasts. Everest Group has not audited such information and assumes no responsibility for independently verifying such information as Everest Group has relied on such information being complete and accurate in all respects. Note, companies mentioned in Products and/or Services may be customers of Everest Group or have interacted with Everest Group in some other way, including, without limitation, participating in Everest Group research activities.